Valvular & structural heart disease
Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis
Main finding · post-TAVI heart failure hospitalizationResult — go to the resultAdjusted hazard ratio 3.060 95% CI 1.090–8.589Authors' conclusion
Our study supports the adverse clinical impact of CHIP in AS patients undergoing TAVI, which could be attributed to systemic inflammation and maladaptive LV remodeling. Prospective trials are anticipated to validate our findings and provide further evidence that CHIP holds the potential of being an actionable therapeutic target in AS.
Study context
- Population
- Severe aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI)severe AS patients enrolled
- Participants
- 110 participants
- Exposure
- Patients carrying clonal hematopoiesis of indeterminate potential (CHIP) vs those without CHIP
- CHIPn = 40
- Outcome
- post-TAVI heart failure hospitalization
- Follow-up
- Median 55.2 months
Main finding
As reported in the abstract
Adjusted hazard ratio
3.060
95% CI 1.090–8.589
P = 0.034
CHIP vs without CHIP
adjusted HR 3.060 (95% CI 1.090–8.589); P = 0.034
Observational data: associations, not effects.
Further findings
CHIP prevalence
- CHIP detected
- 40 (36.4%)
- Most commonly mutated genes: DNMT3A, TET2, and ASXL1
Serum ferritin, left ventricular hypertrophy and diastolic dysfunction
- Patients harboring CHIP had higher serum ferritin levels, as well as echocardiographic evidence of left ventricular hypertrophy and diastolic dysfunction
Original publication
Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis. JACC Adv. Published 8 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it